---
title: Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan
  (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
date: '2024-07-01'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38951245/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240702183523&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSION: The exploratory analysis of this early terminated trial
  suggests that FOLFIRI and OFF have similar efficacy ant toxicity as second-line
  therapy of PDAC after failure of gemcitabine/nab-paclitaxel. Third-line therapy
  regardless of regimen does not provide satisfactory efficacy in this sequential
  treatment ...'
disable_comments: true
---
CONCLUSION: The exploratory analysis of this early terminated trial suggests that FOLFIRI and OFF have similar efficacy ant toxicity as second-line therapy of PDAC after failure of gemcitabine/nab-paclitaxel. Third-line therapy regardless of regimen does not provide satisfactory efficacy in this sequential treatment ...